KR830007635A - 4-아미노-6,7-디메록시-2-피페라지노퀴나졸린 유도체의 제조방법 - Google Patents

4-아미노-6,7-디메록시-2-피페라지노퀴나졸린 유도체의 제조방법 Download PDF

Info

Publication number
KR830007635A
KR830007635A KR1019810005269A KR810005269A KR830007635A KR 830007635 A KR830007635 A KR 830007635A KR 1019810005269 A KR1019810005269 A KR 1019810005269A KR 810005269 A KR810005269 A KR 810005269A KR 830007635 A KR830007635 A KR 830007635A
Authority
KR
South Korea
Prior art keywords
alkyl
group
substituted
compound
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019810005269A
Other languages
English (en)
Inventor
프레이저 캠벨 시몬
마가레트 폴르스 로나
Original Assignee
시. 엘. 클레멘테
화이자 코포레이숀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시. 엘. 클레멘테, 화이자 코포레이숀 filed Critical 시. 엘. 클레멘테
Publication of KR830007635A publication Critical patent/KR830007635A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/42One nitrogen atom
    • C07D251/44One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/42One nitrogen atom
    • C07D251/46One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

4-아미노-6,7-디메톡시-2-피페라지노퀴나졸린 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 일반식(a)의 화합물을 일반식 (b)의 화합물과 반응시킨후 Het가 한로로 치환된 화합물은 일반식 R1R2NH의 아민과 반응시켜 Het가 -NR1R2(R|1및 R2는 후술되는 바와 같음)로 치환된 화합물로 임의로 전환시킴을 특징으로 하는 일반식(I)의 화합물 또는 그의 약학적으로 허용되는 산부가염의 제조방법.
    상기식에서
    "Het"는 탄소원자중 하나에 의해 피페라진환에 연결된 피리미디닐, 피라지닐, 피리다지닐 또는 트리아지닐 그룹이며 이 그룹은 C1-C2알킬, C1-C4알콕시, 하이드록시, 아릴, 아릴옥시, 아릴에 의해 치환된 C1-C4알킬, 아릴로 치환된 C1-C4알콕시, C1-C4알킬티오, 할로 및 -NR1R2(R1은 수소 또는 C1-C4알킬이며 R2는 수소, C1-C4알킬, C3-C7사이클로알킬, 아릴 또는 아릴로 치환된 C1-C4알킬이거나 R1과 R2는 함께 이들이 결합된 질소원자와 함께 1-피롤리디닐 그룹 또는 O, S 및 N중에서 선택된 또다른 복소원자를 임의로 함유하는 6-원환포화 복소환 그룹을 나타낸다)중에서 선택된 하나 또는 두개의 치환체에 의해 임의로 치환되거나 6,7-디메톡시-1,2,3,4-테트라하이드로 이소퀴놀-2-일 그룹에 의해 임의로 치환되고
    A가 용이하게 이탈될 수 있는 그룹이고 B는이거나 B가 용이하게 이탈될 수 있는 그룹이고 A는이다.
  2. 제1항에 있어서, 언급된 용이하게 이탈될 수 있는 그룹이 할로, C1-C4알콕시 또는 C1-C4알킬티오임을 특징으로 하는 방법.
  3. 제1항 또는 2항에 있어서, "Het"가 제1항에서 정의된 1개 또는 2개의 치환체로 임의 치환된 피리미딘-2-일, 피리미딘-4-일, 1,3,5-트리아진-2-일, 피리다진-3-일, 또는 피라진-2-일 그룹인 화합물을 제조하는 방법.
  4. 제1항 내지 3항중의 어느 하나에 있어서 언급된 아릴 및 아릴옥시 그룹이 각기 C1-C4알킬, C1-C4알콕시 및 할로중에서 선택된 1개 또는 2개의 치환체로 임의 치환된 페닐 또는 페녹시인 화합물을 제조하는 방법.
  5. 제1항 내지 4항중의 어느 하나에 있어서, "Het"가 C1-C4알킬, C1-C|4알콕시, 하이드로시, 페닐, 페녹시, C1-C4알킬티오, 할로 및 -NR1R2(이때 R1은 수소 또는 C1-C4알킬이고 R2는 수소, C1-C4알킬, 페닐 또는 C3-C|7사이클로알킬이거나 R1및 R2가 이들이 부착되어 있는 질소원자와 함께 모르폴리노 그룹을 나타냄)중에서 선택된 1개 또는 2개의 치환체로 비치환 또는 치환되거나 언급된 "Het"그룹이 단일한 6,7-디메톡시-1,2,3,4-테트라하이드로 이소퀴놀-2-일 그룹으로 임의 치환된 화합물을 제조하는 방법.
  6. 제1항 내지 5항중의 어느 하나에 있어서, "Het"가
    (a) C1-C4알킬, C1-C4알콕시, 하이드록시, 페닐, 페녹시, C1-C4알킬티오, 할로 또는 -NR1R2(이때 R1은 수소 또는 C1-C4알킬이며 R2는 수소, C1-C4알킬, C3-C7사이클로알킬 또는 페닐이거나 R1과 R2는 이들이 결합된 질소원자와 함께 모르폴리노그룹을 나타낸다)중에서 선택된 하나 또는 2개의 치환체에 의해 치환 또는 비치환된 2-또는 4-피리미디닐이거나, 단일 6,7-디메톡시-1,2,3,4-테트라하이드로 이소퀴놀-2-일 그룹에 의해 치환된 2-또는 4-피리미디닐,
    (b) C1-C4알콕시, 페녹시 및 -NHR2(R2는 수소 또는 C1-C|4알킬이다)중에서 선택된 2개의 치환체에 의해 치환된 1,3,5-트리아진-2-일
    (c) C1-C4알콕시, 하이드록시, 페닐, 페녹시, 할로 및 -N(C1-C4알킬)|2중에서 선택된 1개의 치환체에 의해 치환 또는 비치환된 3-피리다지닐,
    (d) 2-피라지닐 중에서 선택되는 화합물을 제조하는 방법.
  7. 제1항 내지 6항중의 어느 하나에 있어서, "Het"가
    인 화합물을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019810005269A 1980-12-29 1981-12-28 4-아미노-6,7-디메록시-2-피페라지노퀴나졸린 유도체의 제조방법 Ceased KR830007635A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8041411 1980-12-29
GB80.41411 1980-12-29

Publications (1)

Publication Number Publication Date
KR830007635A true KR830007635A (ko) 1983-11-04

Family

ID=10518236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810005269A Ceased KR830007635A (ko) 1980-12-29 1981-12-28 4-아미노-6,7-디메록시-2-피페라지노퀴나졸린 유도체의 제조방법

Country Status (23)

Country Link
US (3) US4435401A (ko)
EP (1) EP0055583B1 (ko)
JP (1) JPS57181068A (ko)
KR (1) KR830007635A (ko)
AR (1) AR228631A1 (ko)
AT (1) ATE15191T1 (ko)
AU (1) AU529367B2 (ko)
CA (1) CA1165318A (ko)
CS (1) CS236667B2 (ko)
DD (1) DD201901A5 (ko)
DE (1) DE3172089D1 (ko)
DK (1) DK152430C (ko)
ES (1) ES508383A0 (ko)
FI (1) FI70411C (ko)
GR (1) GR76980B (ko)
IE (1) IE52232B1 (ko)
IL (1) IL64665A (ko)
NO (1) NO814454L (ko)
PH (1) PH17079A (ko)
PL (2) PL136217B1 (ko)
PT (1) PT74205B (ko)
YU (1) YU312781A (ko)
ZA (1) ZA818932B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
DE3114088A1 (de) * 1981-04-08 1982-10-28 Bayer Ag, 5090 Leverkusen Wasserloesliche triazinverbindungen, ihre herstellung und ihre verwendung
FR2521560A1 (fr) * 1982-02-17 1983-08-19 Adir Nouveaux derives de piperazine et d'homopiperazine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
CH651027A5 (de) * 1982-11-12 1985-08-30 Sandoz Ag Heterocyclische verbindungen, ihre herstellung und verwendung.
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
CA1307786C (en) * 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
JPS6267077A (ja) * 1985-09-18 1987-03-26 Mitsui Petrochem Ind Ltd キナゾリン誘導体及び医薬
JPS61140568A (ja) * 1984-12-14 1986-06-27 Mitsui Petrochem Ind Ltd キナゾリン誘導体及びそれを有効成分とする血圧降下剤
AT384218B (de) * 1985-12-04 1987-10-12 Gerot Pharmazeutika Verfahren zur herstellung von neuen chinazolin-derivaten
US5072564A (en) * 1988-10-11 1991-12-17 Campana Technology, Inc. Decorative panel
DE69120221T2 (de) * 1990-07-03 1996-11-21 Mitsui Petrochemical Ind Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
IT1286302B1 (it) * 1996-04-10 1998-07-08 Rotta Research Lab Chinazoline-4-amino-2-(piperidino-1-il-4-sostituite) ad attivita' anti-ipertensiva, procedimento per la loro preparazione e loro uso
SK285198B6 (sk) * 1997-10-27 2006-08-03 Neurosearch A/S Homopiperazínový derivát, farmaceutická kompozícia obsahujúca tento derivát a jeho použitie
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN101090724A (zh) * 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515477A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
SG182205A1 (en) 2007-03-15 2012-07-30 Novartis Ag Organic compounds and their uses
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
GB201008209D0 (en) * 2010-05-17 2010-06-30 Senexis Ltd Compounds
GB201008210D0 (en) * 2010-05-17 2010-06-30 Senexis Ltd Compounds
WO2024194756A1 (en) 2023-03-17 2024-09-26 Pfizer Inc. Modulating the innate immunity of rna

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) * 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
US3517005A (en) 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3669968A (en) 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
US3900476A (en) 1973-05-17 1975-08-19 Upjohn Co 2(2'-pyrimidylamino)quinazolines and their preparation
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4062844A (en) * 1976-09-20 1977-12-13 Pfizer Inc. Process for preparing hypotensive 2-(4-aroylpiperazin-1-yl)-amino-6,7-dimethoxyquinazolines
US4101548A (en) * 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4171363A (en) 1977-02-22 1979-10-16 Bristol-Myers Company 1,2,3-Thiadiazole process
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4161595A (en) 1978-10-02 1979-07-17 Bristol-Myers Company Levulinic acid salt
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
US4351832A (en) 1980-04-18 1982-09-28 American Home Products Corporation 2-(Piperazinyl)-4-pyrimidinamines
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat

Also Published As

Publication number Publication date
DD201901A5 (de) 1983-08-17
IL64665A (en) 1985-03-31
US4483859A (en) 1984-11-20
JPS57181068A (en) 1982-11-08
NO814454L (no) 1982-06-30
YU312781A (en) 1984-12-31
US4435401A (en) 1984-03-06
DK152430B (da) 1988-02-29
PL243280A1 (en) 1984-04-24
GR76980B (ko) 1984-09-04
EP0055583B1 (en) 1985-08-28
ZA818932B (en) 1982-11-24
IE52232B1 (en) 1987-08-19
PT74205B (en) 1984-11-26
PH17079A (en) 1984-05-24
AU7884681A (en) 1982-07-08
US4483857A (en) 1984-11-20
FI814055L (fi) 1982-06-30
ATE15191T1 (de) 1985-09-15
AR228631A1 (es) 1983-03-30
JPS6136831B2 (ko) 1986-08-20
EP0055583A1 (en) 1982-07-07
PL136217B1 (en) 1986-02-28
PT74205A (en) 1982-01-02
CA1165318A (en) 1984-04-10
DK569781A (da) 1982-06-30
DE3172089D1 (en) 1985-10-03
FI70411C (fi) 1986-09-19
DK152430C (da) 1988-07-25
ES8405787A1 (es) 1984-06-16
IL64665A0 (en) 1982-03-31
ES508383A0 (es) 1984-06-16
FI70411B (fi) 1986-03-27
IE813053L (en) 1982-06-29
AU529367B2 (en) 1983-06-02
PL234523A1 (en) 1983-12-19
CS236667B2 (en) 1985-05-15
PL136268B1 (en) 1986-02-28

Similar Documents

Publication Publication Date Title
KR830007635A (ko) 4-아미노-6,7-디메록시-2-피페라지노퀴나졸린 유도체의 제조방법
Robins Potential purine antagonists. XV. Preparation of some 6, 8-disubstituted purines1
ES8706146A1 (es) Un procedimiento para preparar derivados de piridina
GB915304A (en) Pyrrolo[2,3-d]pyrimidine derivatives
ES8507111A1 (es) Un procedimiento para la preparacion de compuestos de 1,4-dihidropiridina.
GB1120463A (en) Derivatives of 1,3-diazafluoranthene-1-oxide
GB937726A (en) New 4-mercapto-pyrazolo[3,4-d]pyrimidines and process for preparing same
ES418627A1 (es) Procedimiento de preparacion de nuevos derivados organofos-forados.
KR850001213A (ko) 이미다조[1,5-a] 피리미딘 유도체의 제조방법
ES8705889A1 (es) Un metodo para preparar eteres alcaximetilicos y esteres alcoximetilicos de derivados de guananina.
ES332580A1 (es) Un procedimiento para la preparacion de derivados de benzodiacepina.
KR950701916A (ko) 신규한 피페라지닐-비스(알킬아미노)피리미딘 유도체와 그것의 산부가염 및 그들의 제조방법
GB1342024A (en) Triazine herbicides
ES8401057A1 (es) Procedimiento para preparar derivados de piridazinona.
KR850001215A (ko) 5-치환된 [1,2,4]트리아졸로-[1,5-c]피리미딘-2-아민의 제조방법
GB1257259A (ko)
ES418113A1 (es) Un procedimiento para la preparacion de nuevas piperacino- pirimidinas.
Takamizawa et al. Studies on the Pyrimidine Derivatives. XXVII. Reactions of Amidines with 3-Ethoxy-2-methoxymethylenepropionitrile, 3-Ethoxy-2-ethoxymethoxymethyl-propionitrile, Ethyl 3-Ethoxy-2-methoxymethylenepropionate, and Ethyl 3-Ethoxy-2-ethoxymethoxymethylpropionate.
KR840004089A (ko) 구아니디노 헤테로사이클릭페닐아미딘의 제조방법
GB1051006A (ko)
US2489526A (en) Amino pyrimidines
EP0127196A3 (en) Antihypertensive lactams
US2443303A (en) Hydroxypykimidine derivatives
OKADA et al. Syntheses and Antitumor Activities of 5-(Substituted-methyl)-6-carbamoyluracils
ES425093A1 (es) Procedimiento para la preparacion de 2-cloro-4 - alcohila- mino-6-cianoalcohil-amino-1,3,5-triazinas sustituidas.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19811228

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19860503

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19811228

Comment text: Patent Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19870128

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 19870406

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19870128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I